Abeona Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, showing net ZEVASKYN revenue of $11.4 million, a 31% increase from the prior quarter. The company treated five patients with its gene therapy product during the period and holds $146.8 million in cash and short-term investments. Abeona also announced that CMS will grant New Technology Add-On Payment status for ZEVASKYN starting October 1, 2026, facilitating access for Medicare beneficiaries. The company operates as a commercial-stage biopharmaceutical firm developing cell and gene therapies.

At its June 12, 2026 annual meeting, Abeona Therapeutics Inc. stockholders approved increasing the shares reserved for issuance under the Second Amended and Restated 2023 Equity Incentive Plan from 8,400,000 to 11,500,000. Stockholders elected Keith A. Goldan and Bernhardt G. Zeiher, M.D. as Class 1 directors, ratified Deloitte & Touche LLP as the independent auditor, and approved executive compensation. A proposal to remove the advance notice provision for director nominations from the Amended and Restated Certificate of Incorporation failed to receive the required 66 2/3% affirmative vote. The company is a biopharmaceutical company that develops gene therapies.

Michael Amoroso resigned from the Board of Directors and the Nominating and Corporate Governance Committee of Abeona Therapeutics Inc. effective June 11, 2026, citing personal reasons. Abeona Therapeutics Inc. is a biotechnology company focused on developing gene and cell therapies.